Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 33Carcinoma, Non-Small-Cell Lung 19Squamous Cell Carcinoma of Head and Neck 18Esophageal Neoplasms 17Nasopharyngeal Carcinoma 11Head and Neck Neoplasms 11Uterine Cervical Neoplasms 10Pancreatic Neoplasms 9Oropharyngeal Neoplasms 8Esophageal Squamous Cell Carcinoma 6Carcinoma, Squamous Cell 6Stomach Neoplasms 4Neoplasms 4Mouth Neoplasms 4Glioblastoma 4Colorectal Neoplasms 4Carcinoma 4Adenocarcinoma 4Urinary Bladder Neoplasms 3Pathologic Complete Response 3Hypopharyngeal Neoplasms 3Thymoma 2Resectable Esophageal Cancer 2Neoplasms by Site 2Nasopharyngeal Neoplasms 2NSCLC 2Lymphoma 2Lung Neoplasms 2Locally Advanced Malignant Neoplasm 2Laryngeal Neoplasms 2

Interventions

camrelizumab 3apatinib 2Oxaliplatin 2XELOX 1Taxes 1S 1 (combination) 1Laparoscopy 1Gastrectomy 1Conversion to Open Surgery 1Chemoradiotherapy 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Locally Advanced Gastric Cancer × Chemoradiotherapy × Clear all
NCT05528367 2022-09-06

Tirelizumab in Combination With Chemoradiation in Patients With Unresectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Zhejiang Cancer Hospital

Phase 2 Unknown
33 enrolled
Gastrointestinal

Locally Advanced Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡